USING ACAMPROSATE FOR MODULATING ACTIVATION OF ERK1/2 IN ANIMAL MODELS FXS AND ASD AND PEOPLE DIAGNOSED WITH FXS AND ASD Russian patent published in 2019 - IPC G01N33/577 C12Q1/68 A61K31/185 A61K48/00 A61P25/28 

FIELD: medicine.

SUBSTANCE: proposed group of inventions relates to medicine. Disclosed are methods of treating a patient with a diagnosed autism spectrum disorder (ASD) or X-chromosome breaking syndrome (FXS), comprising steps of bringing a patient's blood sample into contact with an antibody that selectively binds ERK 1 or ERK 2, administering acamprosate or a pharmaceutically acceptable acamprosate salt to the patient, determining if there is a change in ERK 1 or ERK 2 levels in the patient's blood and increasing the amount of acamprosate or the pharmaceutically acceptable acamprosate salt so as to reduce the level of at least one of ERK 1 and ERK 2 in patient's peripheral blood. Disclosed is a monitoring system for a patient and a method of screening for a compound used in treating idiopathic ASD or ASD associated with FXS.

EFFECT: proposed group of inventions provides biomarkers for developing purposeful treatment of ASD or FXS.

18 cl, 4 dwg, 10 tbl